Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Evolving concepts in HER2 evaluation in breast cancer: Heterogeneity, HER2-low carcinomas and beyond.

Seminars in cancer biology - 1 Jul 2021

Marchiò Caterina, Annaratone Laura, Marques Ana, Casorzo Laura, Berrino Enrico, Sapino Anna

Abstract excerpt

The human epidermal growth factor receptor 2 (HER2) is a well-known negative prognostic factor in breast cancer and a target of the monoclonal antibody trastuzumab as well as of other anti-HER2 compounds. Pioneering works on HER2-positive breast cancer in the 90s' launched a new era in clinical research and oncology practice that has reshaped the natural history of this disease. In diagnostic pathology the HER2...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Breast Neoplasms

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Gene Amplification

Share to Mutation

Share to Prognosis

Share to Receptor, ErbB-2

Source

Identifiers

PMID: 32112814
DOI: 10.1016/j.semcancer.2020.02.016

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Evolving concepts in HER2 evaluation in breast cancer: Heterogeneity, HER2-low carcinomas and beyond.PMID 32112814Read ↗

HER2 Low, Ultra-low, and Novel Complementary Biomarkers: Expanding the Spectrum of HER2 Positivity in Breast CancerSemantic proximity Read ↗

Unusual Patterns of HER2 Expression in Breast Cancer: Insights and PerspectivesSemantic proximity Read ↗

Deciphering HER2 Breast Cancer Disease: Biological and Clinical ImplicationsSemantic proximity Read ↗

The trichotomy of HER2 expression confers new insights into the understanding and managing for breast cancer stratified by HER2 statusSemantic proximity Read ↗

Exploring the Heterogeneity of HER2 gene status and Expression in Non-Positive Breast Cancer Patients: Insights from Immunohistochemistry and Fluorescence In Situ HybridizationSemantic proximity Read ↗

Advances in EGFR/HER2-directed clinical research on breast cancer.Semantic proximity Read ↗

HER2 in solid tumors: more than 10 years under the microscope; where are we now?Semantic proximity Read ↗

Intra-tumor genetic heterogeneity and alternative driver genetic alterations in breast cancers with heterogeneous HER2 gene amplification.Semantic proximity Read ↗

Molecular Targeting the Human Epidermal Growth Factor Receptor-2 (HER2) Genes Across Various CancerSemantic proximity Read ↗

Integrative genomic and transcriptomic analyses illuminate the ontology of HER2-low breast carcinomas.Semantic proximity Read ↗

Low and Ultra-low HER2 in Human Breast Cancer: An Effort to Define New Neoplastic SubtypesSemantic proximity Read ↗

Molecular Targeting of the Human Epidermal Growth Factor Receptor-2 (HER2) Genes across Various CancersSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.